Comparison Between a Liquid Chromatography-tandem Mass Spectrometry Assay and a Fluorescent Polarization Immunoassay to Measure Whole Blood Everolimus Concentration in Heart and Renal Transplantations

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2008 Jul 16

PMID 18623123

Authors

Eric Dailly

G Deslandes

M Hourmant

T Petit

C Renaud

M Treilhaud

P Jolliet

Affiliations

Soon will be listed here.

Abstract

Various methods [fluorescent polarization immunoassay (FPIA) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay] are used for therapeutic drug monitoring of everolimus. The aim of this study is to compare these assays in renal and heart transplantation. The correlation between results was investigated by linear regression in 44 patients (24 heart recipients and 20 renal recipients--137 samples). The comparison between assays was performed by a paired t-test. A highly significant correlation was found between FPIA and LC-MS/MS in heart and renal recipients [FPIA=0.851 x LC-MS/MS+1.773r(2)=0.8738 (P<0.001)]. Paired t-tests did not show a significant difference between everolimus whole blood concentrations in the populations of heart and renal recipients or heart recipients or renal recipients. FPIA and LC-MS/MS assays gave consistent overall results although some significant differences were observed in some samples between these methods indicating that FPIA assay has limitations that deserve further investigations.

References

Koal T, Deters M, Casetta B, Kaever V . Simultaneous determination of four immunosuppressants by means of high speed and robust on-line solid phase extraction-high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 805(2):215-22. DOI: 10.1016/j.jchromb.2004.02.040. View

Oellerich M, Armstrong V . The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. Ther Drug Monit. 2006; 28(6):720-5. DOI: 10.1097/FTD.0b013e31802c5cf5. View

Dunn C, Croom K . Everolimus: a review of its use in renal and cardiac transplantation. Drugs. 2006; 66(4):547-70. DOI: 10.2165/00003495-200666040-00009. View

Strom T, Haschke M, Boyd J, Roberts M, Arabshahi L, Marbach P . Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. Ther Drug Monit. 2007; 29(6):743-9. DOI: 10.1097/FTD.0b013e31815b3cbf. View

Taylor P . Internal standard selection for immunosuppressant drugs measured by high-performance liquid chromatography tandem mass spectrometry. Ther Drug Monit. 2007; 29(1):131-2. DOI: 10.1097/FTD.0b013e31802c0787. View